1258 related articles for article (PubMed ID: 22405266)
1. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
2. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
4. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide in oral antidiabetic drug combination therapy.
Garber AJ
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
[TBL] [Abstract][Full Text] [Related]
6. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in incretin-based therapies.
Russell-Jones D; Gough S
Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
[TBL] [Abstract][Full Text] [Related]
8. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Davies M; Speight J
Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
[TBL] [Abstract][Full Text] [Related]
10. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
11. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
14. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide: effects beyond glycaemic control in diabetes treatment.
McGill JB
Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
